Clinical Benefit experienced with NUCALA

Clinical Benefit was defined as1:

Remission*

BVAS=0 (no active vasculitis) plus OCS dose ≤4 mg/day

and/or

≥50% reduction

from baseline in average OCS dose during Weeks 48 to 52

and/or

No relapse

Post hoc analysis: A higher proportion of patients experienced a Clinical Benefit1

Graph displaying patients experienced a Clinical Benefit
Graph displaying patients experienced a Clinical Benefit

Results are descriptive

Percentage of patients who experienced all three components of Clinical Benefit1

Clinical Benefit Pie charts

29%

NUCALA + SOC
(n=20/68)

VS

Clinical Benefit Pie charts

7%

Placebo + SOC
(n=5/68)

Post hoc analysis. All results are descriptive.

Post hoc analysis: A higher proportion of patients experienced each component of Clinical Benefit1

Graph displaying Clinical Benefit
Graph displaying Clinical Benefit

Results are descriptive.

The study definition of remission was more stringent than the EULAR (European League Against Rheumatism) definition of remission (BVAS=0 and OCS dose ≤7.5 mg/day).2,3

Remission was defined as Birmingham Vasculitis Activity Score (BVAS)=0 (no active vasculitis) plus prednisolone or prednisone dose less than or equal to 4 mg/day.1

Relapse was defined as a worsening related to vasculitis, asthma, or sinonasal symptoms requiring an increase in dose of corticosteroids, increase in dose or addition of immunosuppressive therapy, or hospitalization.1

BVAS=Birmingham Vasculitis Activity Score; OCS=oral corticosteroid; SOC=standard of care.

See clinical efficacy for NUCALA